Otsuka Pharmaceutical Factory has reached an agreement with Mitsui & Co to acquire a remaining 20% interest in Otsuka Pharmaceutical India Private from the Mitsui.

The acquisition will make Otsuka Pharmaceutical India Private a wholly-owned subsidiary of Otsuka Pharmaceutical Factory.

In 2013, Otsuka Pharmaceutical Factory established Otsuka Pharmaceutical India Private as part of a joint venture (JV) with Claris Lifesciences (owning a 20% stake) and Mitsui (20%). The final 20% was owned by Claris, which was acquired by

“Shin Kowa Pharmaceutical has acquired Hakushindo Pharmaceutical.”

Otsuka Pharmaceutical Factory acquired a 20% stake held by Claris in September 2017.

Mitsui is a diversified trading company based in Japan. Otsuka Pharmaceutical India Private provides intravenous and clinical nutrition products.

Shin Kowa Pharmaceutical has acquired Hakushindo Pharmaceutical.

Shin Kowa Pharmaceutical produces NMN (ß nicotinamide mononucleotide). The firm expects the acquisition to enable it to build up the clinical trial results database of the Hiroshima University Graduate School of Biomedical & Health Sciences Project Research Center.